GLP1R and obesity due to melanocortin 4 receptor deficiency: These findings still suggest that GLP-1 + PYY3-36 combination therapy holds genuine promise as a noninvasive alternative to RYGB for treating obesity, although these peptides are probably not the only or main factors for the effects and actions of RYGB.